{"entity":{"id":"nct03414658","kind":"trial","name":"AVIATOR","aka":["The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer"],"tldr":"AVIATOR compares trastuzumab and vinorelbine with combinations that add avelumab, with or without utomilumab. It asks whether the added immune treatments improve control of advanced HER2-positive breast cancer.","summary":"AVIATOR compares trastuzumab and vinorelbine with combinations that add avelumab, with or without utomilumab. It asks whether the added immune treatments improve control of advanced HER2-positive breast cancer.\n\nInterventional study registered as NCT03414658, sponsored by Adrienne G. Waks. Registry phase: 2. Registry enrollment is 100 participants (actual). Registry status checked October 10, 2026: active not recruiting. UCSF lists this study as closed to local enrollment; local availability and overall registry status are separate. See the registry for full eligibility and current sites.","status":"active","asOf":"2026-10-10","links":[{"label":"ClinicalTrials.gov NCT03414658","url":"https://clinicaltrials.gov/study/NCT03414658"},{"label":"UCSF study listing and local availability","url":"https://clinicaltrials.ucsf.edu/trial/NCT03414658"}],"tags":["ucsf-breast-coverage","interventional"],"related":[],"cancers":["breast-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["avelumab","trastuzumab","utomilumab","vinorelbine"],"companies":[],"institutions":["ucsf"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03414658","phase":"2","setting":"Advanced HER2-positive breast cancer","sponsor":"Adrienne G. Waks","participation":[{"nct":"NCT03414658","source":"https://clinicaltrials.gov/study/NCT03414658","fetchedAt":"2026-10-10T20:54:20.453662Z","studySha256":"cde41b3c720457e996dee0b9207492ea979992092fa18362b5825b1b2f6c3f73","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2026-07-20","leadSponsor":"Adrienne G. Waks","collaboratorCount":3,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":100,"enrolmentType":"ACTUAL","siteCount":17,"recruitingSiteCount":0,"countries":["United States"]}],"started":"2018-06-21","startedType":"actual","enrolled":100,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct03414658/","neighbours":{"cancer":[{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"}],"drug":[{"id":"avelumab","kind":"drug","name":"Avelumab","route":"/drugs/avelumab/"},{"id":"trastuzumab","kind":"drug","name":"Trastuzumab","route":"/drugs/trastuzumab/"},{"id":"utomilumab","kind":"drug","name":"Utomilumab","route":"/drugs/utomilumab/"},{"id":"vinorelbine","kind":"drug","name":"Vinorelbine","route":"/drugs/vinorelbine/"}],"institution":[{"id":"ucsf","kind":"institution","name":"UCSF Helen Diller Family Comprehensive Cancer Center","route":"/institutions/ucsf/"}]}}